CHEBI:92897 - Ro 25-6981

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name Ro 25-6981
ChEBI ID CHEBI:92897
Definition A member of the class of piperidines that is 4-benzylpiperidine substituted by a 3-hydroxy-3-(4-hydroxyphenyl)-2-methylpropyl group at position 1 (the 1R,2S-stereoisomer). It is a potent antagonist of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
more structures >>
Formula C22H29NO2
Net Charge 0
Average Mass 339.479
Monoisotopic Mass 339.21983
InChI InChI=1S/C22H29NO2/c1-17(22(25)20-7-9-21(24)10-8-20)16-23-13-11-19(12-14-23)15-18-5-3-2-4-6-18/h2-10,17,19,22,24-25H,11-16H2,1H3/t17-,22+/m0/s1
InChIKey WVZSEUPGUDIELE-HTAPYJJXSA-N
SMILES C[C@@H](CN1CCC(CC2=CC=CC=C2)CC1)[C@@H](O)C1=CC=C(O)C=C1
Roles Classification
Chemical Role(s): Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Biological Role(s): NMDA receptor antagonist
Any substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs.
Application(s): anticonvulsant
A drug used to prevent seizures or reduce their severity.
antidepressant
Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
neuroprotective agent
Any compound that can be used for the treatment of neurodegenerative disorders.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing Ro 25-6981 (CHEBI:92897) has role anticonvulsant (CHEBI:35623)
Ro 25-6981 (CHEBI:92897) has role antidepressant (CHEBI:35469)
Ro 25-6981 (CHEBI:92897) has role neuroprotective agent (CHEBI:63726)
Ro 25-6981 (CHEBI:92897) has role NMDA receptor antagonist (CHEBI:60643)
Ro 25-6981 (CHEBI:92897) is a benzenes (CHEBI:22712)
Ro 25-6981 (CHEBI:92897) is a phenols (CHEBI:33853)
Ro 25-6981 (CHEBI:92897) is a piperidines (CHEBI:26151)
Ro 25-6981 (CHEBI:92897) is a secondary alcohol (CHEBI:35681)
Ro 25-6981 (CHEBI:92897) is a tertiary amino compound (CHEBI:50996)
Ro 25-6981 (CHEBI:92897) is conjugate base of Ro 25-6981(1+) (CHEBI:183314)
Incoming Ro 25-6981(1+) (CHEBI:183314) is conjugate acid of Ro 25-6981 (CHEBI:92897)
IUPAC Name
4-[(1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol
Synonyms Sources
RS)-α-(4-Hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol ChEBI
4-[(1R,2S)-1-hydroxy-2-methyl-3-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol ChEBI
Ro 25-6981 free base ChEBI
Ro-25-6981 ChEBI
Ro25-6981 ChEBI
Manual Xrefs Databases
5037146 ChemSpider
LSM-3140 LINCS
QEM PDBeChem
View more database links
Registry Number Type Source
169274-78-6 CAS Registry Number ChEBI
Citations Waiting for Citations Types Sources
11290368 PubMed citation Europe PMC
12498913 PubMed citation Europe PMC
14534359 PubMed citation Europe PMC
15081591 PubMed citation Europe PMC
15256539 PubMed citation Europe PMC
17970830 PubMed citation Europe PMC
18809426 PubMed citation Europe PMC
21598675 PubMed citation Europe PMC
21677647 PubMed citation Europe PMC
23113280 PubMed citation Europe PMC
24076088 PubMed citation Europe PMC
24893066 PubMed citation Europe PMC
25008524 PubMed citation Europe PMC
25446739 PubMed citation Europe PMC
27062927 PubMed citation Europe PMC
27456026 PubMed citation Europe PMC
27871866 PubMed citation Europe PMC
28802646 PubMed citation Europe PMC
29777135 PubMed citation Europe PMC
29790100 PubMed citation Europe PMC
29800545 PubMed citation Europe PMC
29862605 PubMed citation Europe PMC
32640759 PubMed citation Europe PMC
32925228 PubMed citation Europe PMC
34363521 PubMed citation Europe PMC
34453973 PubMed citation Europe PMC
34575558 PubMed citation Europe PMC
9400004 PubMed citation Europe PMC
9572302 PubMed citation Europe PMC
Last Modified
04 November 2021